Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML

Leukemia

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

Blood Cancer J

Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C

doi: 10.1038/s41408-025-01269-x

Multiple Myeloma (MM)

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry

Blood Cancer J

Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto CJ, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Joshi P, Jou YM, Mouro J, Yu E, Abonour R

doi: 10.1038/s41408-024-01177-6

Multiple Myeloma (MM)

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

Lancet Haematol

Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J

doi: 10.1016/S2352-3026(25)00143-7

ASH 2024

Leukemia

Quizartinib significantly reduces relapse rates versus midostaurin in newly diagnosed patients with FLT3-ITD-positive AML, based on MAIC analysis

ASH 2024

Leukemia

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

Leukemia

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial

Haematologica

Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, Žak P, Wang PN, Hanyok J, Liu L, Kamel YM, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP

doi: 10.3324/haematol.2024.286623

Gynecologic Cancer

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update

J Clin Oncol

Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, Ghebre RG, Gressel GM, Lesnock JL, Meyer LA, Moore KN, O'Cearbhaill RE, Olawaiye AB, Salani R, Sparacio D, van Driel WJ, Tew WP

doi: 10.1200/JCO-24-02589

Head and Neck Cancer

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial

JAMA Oncol

Guo SS, Li XY, Liu LT, Jia GD, Liu SL, Sun XS, Luo DH, Yang JH, Xie SY, Li YF, Lv X, Xiang YQ, Xia WX, Sun R, Liu Q, Li JB, Wang P, Yang Q, Wang L, Wen DX, Jin J, Lin JY, Mo HY, Guo L, Zhao C, Guo X, Chen QY, Tang LQ, Mai HQ

doi: 10.1001/jamaoncol.2025.1597

Multiple Myeloma (MM)

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Lancet Oncol

Mateos MV, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Ngo M, Katz EG, Krevvata M, Bolyard K, Carson R, Borgsten F, Dimopoulos MA

doi: 10.1016/S1470-2045(25)00018-X

Related content

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry

Quizartinib significantly reduces relapse rates versus midostaurin in newly diagnosed patients with FLT3-ITD-positive AML, based on MAIC analysis

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial